Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Clicking and dragging the fill handle in Microsoft Excel to create a numbered list is unreliable, non-dynamic, and time-consuming, especially if the list is lengthy. Instead, you can combine two of ...

DNA Ginkgo Bioworks Holdings, Inc.

Despite his title disappointment, Oscar Piastri says he is determined to regain the feeling he felt at times during his 2025 F1 campaign Lando Norris said made changes in the autumn ‘to unlock more of ...

Thanks to the Human Genome Project, researchers have sequenced all 3.2 billion base pairs in the human genome. How did researchers complete this chromosome map years ahead of schedule? Initial ...